News - GlaxoSmithKline, Votrient

Filter

Current filters:

GlaxoSmithKlineVotrient

Popular Filters

Renal cell cancer market to rapidly decline from 2019

Renal cell cancer market to rapidly decline from 2019

24-12-2013

The renal cell cancer market is expected to peak at a value of $2.7 billion in 2019, before significantly…

AfinitorAvastinBayerFinancialGlaxoSmithKlineInlytaMarkets & MarketingNexavarNorthern EuropeNovartisOncologyPfizerPharmaceuticalRocheSutentToriselUSAVotrient

GlaxoSmithKline files for expanded use for Votrient

07-08-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) says it has submitted a request to the European Medicines…

EuropeGlaxoSmithKlineOncologyPharmaceuticalRegulationVotrient

Prognosis for renal cell carcinoma market development

27-11-2012

Through 2021, small-molecule angiogenesis inhibitors will dominate the renal cell carcinoma (RCC) drug…

Bristol-Myers SquibbGlaxoSmithKlineGlobalMarkets & MarketingnivolumabOncologyPfizerPharmaceuticalSutentVotrient

EMA approves GlaxoSmithKline's Votrient for soft tissue sarcomas

09-08-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) says that the European Medicines Agency has approved Votrient…

EuropeGlaxoSmithKlineOncologyPharmaceuticalRegulationVotrient

US FDA backs new indications for Votrient and Afinitor

29-04-2012

The US Food and Drug Administration last week gave its approval for new indications for currently marketed…

AfinitorGlaxoSmithKlineNorth AmericaNovartisOncologyPharmaceuticalRegulationVotrient

FDA panel backs GlaxoSmithKline sarcoma drug Votrient

21-03-2012

Providing welcome news for UK pharma giant GlaxoSmithKline (LSE: GSK), the Oncologic Drugs Advisory Committee…

GlaxoSmithKlineNorth AmericaOncologyPharmaceuticalRegulationVotrient

New Zealand to fund new cancer drugs Tykerb and Votrient

05-03-2012

The Pharmaceutical Management Agency of New Zealand, PHARMAC, says it is funding two new targeted cancer…

Asia-PacificGlaxoSmithKlineOncologyPharmaceuticalPricingRegulationTykerbVotrient

Robust growth forecast for renal cell carcinoma market

11-12-2011

The renal cell carcinoma drug market will experience robust 3.7% annual growth from 2010 to 2020 in the…

axitinibdovitinibGlaxoSmithKlineMarkets & MarketingNephrology and HepatologyNovartisOncologyPfizerPharmaceuticalSutentVotrient

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top